IL92352A - A method for stimulating bone marrow cells - Google Patents
A method for stimulating bone marrow cellsInfo
- Publication number
- IL92352A IL92352A IL9235289A IL9235289A IL92352A IL 92352 A IL92352 A IL 92352A IL 9235289 A IL9235289 A IL 9235289A IL 9235289 A IL9235289 A IL 9235289A IL 92352 A IL92352 A IL 92352A
- Authority
- IL
- Israel
- Prior art keywords
- bone marrow
- carbon atoms
- cells
- compound
- marrow cells
- Prior art date
Links
- 210000002798 bone marrow cell Anatomy 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000000638 stimulation Effects 0.000 title abstract 2
- 230000004069 differentiation Effects 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 46
- 125000004432 carbon atom Chemical group C* 0.000 claims description 32
- 210000001185 bone marrow Anatomy 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 19
- -1 tellurium ions Chemical class 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 229910052714 tellurium Inorganic materials 0.000 claims description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 210000002449 bone cell Anatomy 0.000 claims description 7
- 230000003750 conditioning effect Effects 0.000 claims description 5
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 claims description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 claims description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 150000003498 tellurium compounds Chemical class 0.000 abstract description 3
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 14
- 210000000130 stem cell Anatomy 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 210000003593 megakaryocyte Anatomy 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 210000000267 erythroid cell Anatomy 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010021460 Immunodeficiency syndromes Diseases 0.000 description 1
- 102100020873 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 231100000818 accidental exposure Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000002507 cathodic stripping potentiometry Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019980 sodium acid phosphate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- XSOKHXFFCGXDJZ-UHFFFAOYSA-N telluride(2-) Chemical compound [Te-2] XSOKHXFFCGXDJZ-UHFFFAOYSA-N 0.000 description 1
- 150000003497 tellurium Chemical class 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/278,957 US4946437A (en) | 1988-12-02 | 1988-12-02 | Method for the stimulation of bone marrow cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL92352A true IL92352A (en) | 1996-03-31 |
Family
ID=23067108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9235289A IL92352A (en) | 1988-12-02 | 1989-11-17 | A method for stimulating bone marrow cells |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4946437A (de) |
| EP (1) | EP0372620B1 (de) |
| JP (1) | JP3067779B2 (de) |
| KR (1) | KR100200185B1 (de) |
| AT (1) | ATE94060T1 (de) |
| AU (1) | AU629577B2 (de) |
| CA (1) | CA2004461C (de) |
| DE (1) | DE68909015T2 (de) |
| DK (1) | DK607889A (de) |
| IL (1) | IL92352A (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2363965C (en) | 1991-03-11 | 2010-05-18 | Curis, Inc. | Protein-induced morphogenesis |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| US5460964A (en) * | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| US5436151A (en) * | 1992-04-03 | 1995-07-25 | Regents Of The University Of Minnesota | Method for culturing human hematopoietic stem cells in vitro |
| US5547931A (en) * | 1994-02-23 | 1996-08-20 | Immtech International Inc. | Methods of stimulatory thrombocytopoiesis using modified C-reactive protein |
| DE69534535T2 (de) * | 1994-12-15 | 2006-07-06 | Baker Norton Pharmaceuticals, Inc., Miami | Verfahren und mittel zur verminderung der tumorentwicklung mittels einer kombination aus einer taxanverbindung und einer tellur und/oder selenverbindung |
| US6013067A (en) * | 1995-06-07 | 2000-01-11 | Zymogenetics, Inc. | Methods for increasing hematopoietic cells |
| US7045150B2 (en) * | 2001-07-31 | 2006-05-16 | Tellus Biotech Ltd. | Tellurium containing nutrient formulation and process for enhancing the cumulative weight gain or feed efficacy in poultry |
| GB201017247D0 (en) * | 2010-10-13 | 2010-11-24 | Islam Abul B M | Injection port for intra-marrow injection/fusion |
| HK1197262A1 (en) * | 2011-02-18 | 2015-01-09 | 永生细胞公司 | Stem cells packaging and shipping |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4481946A (en) * | 1980-08-14 | 1984-11-13 | Altshuler John H | Bone marrow transplant method and apparatus |
| US4486188A (en) * | 1980-08-14 | 1984-12-04 | Applied Medical Devices, Inc. | Bone marrow transplant method and apparatus |
| SU952189A1 (ru) * | 1980-08-19 | 1982-08-23 | Киевский научно-исследовательский институт ортопедии | Способ извлечени клеток костного мозга и консервирующих растворов из губчатого костного трансплантата |
| US4861704A (en) * | 1983-09-01 | 1989-08-29 | The Trustees Of Columbia University In The City Of New York | Processes for development of acceptance of transplanted organs and tissues |
| US4761490A (en) * | 1985-03-15 | 1988-08-02 | Bar-Ilan University | Organic derivatives of tellurium and selenium and their use to stimulate cytokine production |
| US4962207A (en) | 1985-09-30 | 1990-10-09 | Bar-Ilan University | Organic derivatives of tellurium and selenium |
| US4752614A (en) * | 1985-09-30 | 1988-06-21 | Bar-Ilan University | Pharmaceutical compositions of tellerium and selenium compounds for the induction of in vivo and in vitro production of cytokines |
| US4838852A (en) * | 1987-03-27 | 1989-06-13 | Therakos, Inc. | Active specific immune suppression |
| NZ228144A (en) | 1988-03-14 | 1991-03-26 | Univ Bar Ilan | Complexes of te and se, and methods of stimulating cells using them |
-
1988
- 1988-12-02 US US07/278,957 patent/US4946437A/en not_active Expired - Lifetime
-
1989
- 1989-11-17 IL IL9235289A patent/IL92352A/en not_active IP Right Cessation
- 1989-11-27 EP EP19890203002 patent/EP0372620B1/de not_active Expired - Lifetime
- 1989-11-27 DE DE89203002T patent/DE68909015T2/de not_active Expired - Fee Related
- 1989-11-27 AT AT89203002T patent/ATE94060T1/de not_active IP Right Cessation
- 1989-11-28 AU AU45633/89A patent/AU629577B2/en not_active Ceased
- 1989-11-30 KR KR1019890017531A patent/KR100200185B1/ko not_active Expired - Fee Related
- 1989-12-01 JP JP1314118A patent/JP3067779B2/ja not_active Expired - Lifetime
- 1989-12-01 CA CA002004461A patent/CA2004461C/en not_active Expired - Fee Related
- 1989-12-01 DK DK607889A patent/DK607889A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE68909015T2 (de) | 1994-02-24 |
| JP3067779B2 (ja) | 2000-07-24 |
| EP0372620A2 (de) | 1990-06-13 |
| AU629577B2 (en) | 1992-10-08 |
| CA2004461C (en) | 2002-02-19 |
| KR900009085A (ko) | 1990-07-02 |
| DK607889D0 (da) | 1989-12-01 |
| EP0372620A3 (de) | 1991-03-20 |
| AU4563389A (en) | 1990-06-21 |
| US4946437A (en) | 1990-08-07 |
| KR100200185B1 (ko) | 1999-06-15 |
| CA2004461A1 (en) | 1990-06-02 |
| JPH02200630A (ja) | 1990-08-08 |
| EP0372620B1 (de) | 1993-09-08 |
| DE68909015D1 (de) | 1993-10-14 |
| DK607889A (da) | 1990-06-03 |
| ATE94060T1 (de) | 1993-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6897060B1 (en) | Composition comprising multipotent neural stem cells for generation of hematopoietic cells | |
| Palacios et al. | IL3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo | |
| Virolainen | Hematopoietic origin of macrophages as studied by chromosome markers in mice | |
| Morrissey et al. | The influence of IL-1 treatment on the reconstitution of the hemopoietic and immune systems after sublethal radiation. | |
| AU625644B2 (en) | Bone marrow suppressing agents | |
| US5633426A (en) | In vivo use of human bone marrow for investigation and production | |
| SI9620116A (sl) | Stimulatorni faktor dendritičnih celic | |
| IL92352A (en) | A method for stimulating bone marrow cells | |
| Rennick et al. | In vivo administration of antibody to interleukin-5 inhibits increased generation of eosinophils and their progenitors in bone marrow of parasitized mice | |
| JPH07503706A (ja) | ヒト造血細胞を有するキメラ哺乳動物 | |
| US4976950A (en) | Bone marrow suppressing agents | |
| Deeg et al. | High-dose total-body irradiation and autologous marrow reconstitution in dogs: Dose-rate-related acute toxicity and fractionation-dependent long-term survival | |
| Ruscetti et al. | Reduced blood and marrow neutrophils and granulocytic colony-forming cells in Sl/Sld mice | |
| CA2155515A1 (en) | Expansion of stem cells in long term bone marrow cultures by neutralization of tgf-.beta. | |
| Rossi et al. | Brief communication: Inhibitory effect of interferon on multiplication of friend leukemia cells in vivo | |
| Suit et al. | Quantitative transplantation assays of spontaneous tumors of the C3H mouse as allografts in athymic NCr/Sed-nu/nu nude mice and isografts in C3Hf/Sed mice | |
| Meck et al. | Hematopoiesis versus osteogenesis in ectopic bone marrow transplants | |
| Schriber et al. | Use and toxicity of the colony-stimulating factors | |
| Dexter | Synergistic interactions in haemopoiesis: biological implications and clinical use | |
| IE63675B1 (en) | Complexes of tellurium and selenium derivatives | |
| Stoppa et al. | Liquid culture and cryopreservation of marrow cells of leukaemic patients prior to autologous bone marrow transplantation | |
| Reddi et al. | Obligatory transformation of fibroblasts by bone matrix in rats fed sucrose ration | |
| Taskin et al. | Myelofibrosis: experimental models and human studies | |
| Kodama et al. | Response of newly established mouse myeloid leukemic cell lines to MC3T3-G2/PA6 preadipocytes and hematopoietic factors | |
| Schuening et al. | Retroviral transfer of genes into canine hematopoietic progenitor cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| RH | Patent void | ||
| NE | Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967) | ||
| KB | Patent renewed | ||
| RH1 | Patent not in force |